Dendritic cell-based vaccine efficacy: Aiming for hot spots

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Pizzurro, Gabriela Andrea ^a   Barrio, María Marcela ^a  

^a Centro de Investigaciones Oncologicas (CIOFUCA)   (Argentina)

Author keywords

Antitumor T cells; Cancer vaccines; Dendritic cells; Draining lymph nodes; Immunotherapy; Vaccine injection site

Indexed keywords

DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL INTERACTION; CELL MATURATION; CELL MIGRATION; CELL VIABILITY; CELLULAR IMMUNITY; DRUG EFFICACY; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; INJECTION SITE; LYMPH NODE; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 84926629603     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00091     Document Type: Review

References (107)

1. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 15(9):969-75. doi: 10.1634/theoncologist.2010-0129.
2. Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 119:421-75. doi:10.1016/B978-0-12-407190-2.00007-1.
3. Palucka K, Ueno H, Roberts L, Fay J, Banchereau J. Dendritic cells: are they clinically relevant? Cancer J (2010) 16(4):318-24. doi:10.1097/PPO.0b013e3181eaca83.
4. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 39(1):38-48. doi:10.1016/j.immuni.2013.07.004.
5. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 39(1):1-10. doi:10.1016/j.immuni.2013.07.012.
6. Butterfield LH. Dendritic cells in cancer immunotherapy clinical trials: are we making progress? Front Immunol (2013) 4:454. doi:10.3389/fimmu.2013.00454.
7. Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1(7):1111-34. doi:10.4161/onci.21494.
8. Depillis L, Gallegos A, Radunskaya A. A model of dendritic cell therapy for melanoma. Front Oncol (2013) 3:56. doi:10.3389/fonc.2013.00056.
9. Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, et al. Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res (2011) 50(2-3):235-47. doi:10.1007/s12026-011-8224-z.
10. Pinzon-Charry A, Maxwell T, Lopez JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol (2005) 83(5):451-61. doi:10.1111/j.1440-1711.2005.01371.x.
11. Herber DL, Cao W, Nefedova Y, Novitskiy SV, Nagaraj S, Tyurin VA, et al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 16(8):880-6. doi:10.1038/nm.2172.
12. Alters SE, Gadea JR, Holm B, Lebkowski J, Philip R. IL-13 can substitute for IL-4 in the generation of dendritic cells for the induction of cytotoxic T lymphocytes and gene therapy. J Immunother (1999) 22(3):229-36. doi:10.1097/00002371-199905000-00005.
13. Reichardt P, Dornbach B, Gunzer M. APC, T cells, and the immune synapse. Curr Top Microbiol Immunol (2010) 340:229-49. doi:10.1007/978-3-642-03858-7_12.
14. Linette GP, Carreno BM. Dendritic cell-based vaccines: shining the spotlight on signal 3. Oncoimmunology (2013) 2(11):e26512. doi:10.4161/onci.26512.
15. Delamarre L, Mellman I. Harnessing dendritic cells for immunotherapy. Semin Immunol (2011) 23(1):2-11. doi:10.1016/j.smim.2011.02.001.
16. Frankenberger B, Schendel DJ. Third generation dendritic cell vaccines for tumor immunotherapy. Eur J Cell Biol (2012) 91(1):53-8. doi:10.1016/j.ejcb.2011.01.012.
17. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol (1997) 27(12):3135-42. doi:10.1002/eji.1830271209.
18. Boullart AC, Aarntzen EH, Verdijk P, Jacobs JF, Schuurhuis DH, Benitez-Ribas D, et al. Maturation of monocyte-derived dendritic cells with toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration. Cancer Immunol Immunother (2008) 57(11):1589-97. doi:10.1007/s00262-008-0489-2.
19. Marongiu L, Donini M, Toffali L, Zenaro E, Dusi S. ESAT-6 and HspX improve the effectiveness of BCG to induce human dendritic cells-dependent Th1 and NK cells activation. PLoS One (2013) 8(10):e75684. doi:10.1371/journal.pone.0075684.
20. Sheng KC, Day S, Wright MD, Stojanovska L, Apostolopoulos V. Enhanced dendritic cell-mediated antigen-specific CD4+ T cell responses: IFN-gamma aids TLR stimulation. J Drug Deliv (2013) 2013:516749. doi:10.1155/2013/516749.
21. Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, et al. Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res (2004) 64(17):5934-7. doi:10.1158/0008-5472.CAN-04-1261.
22. Hansen M, Met O, Svane IM, Andersen MH. Cellular based cancer vaccines: type 1 polarization of dendritic cells. Curr Med Chem (2012) 19(25):4239-46. doi:10.2174/092986712802884213.
23. Dauer M, Obermaier B, Herten J, Haerle C, Pohl K, Rothenfusser S, et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol (2003) 170(8):4069-76. doi:10.4049/jimmunol.170.8.4069.
24. Spranger S, Javorovic M, Burdek M, Wilde S, Mosetter B, Tippmer S, et al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol (2010) 185(1):738-47. doi:10.4049/jimmunol.1000060.
25. Sparber F, Tripp CH, Hermann M, Romani N, Stoitzner P. Langerhans cells and dermal dendritic cells capture protein antigens in the skin: possible targets for vaccination through the skin. Immunobiology (2010) 215(9-10):770-9. doi:10.1016/j.imbio.2010.05.014.
26. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity (2010) 33(4):464-78. doi:10.1016/j.immuni.2010.10.007.
27. Fehres CM, Garcia-Vallejo JJ, Unger WW, van Kooyk Y. Skin-resident antigen-presenting cells: instruction manual for vaccine development. Front Immunol (2013) 4:157. doi:10.3389/fimmu.2013.00157.
28. Cohn L, Delamarre L. Dendritic cell-targeted vaccines. Front Immunol (2014) 5:255. doi:10.3389/fimmu.2014.00255.
29. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med (2013) 19(4):465-72. doi:10.1038/nm.3105.
30. Dubensky TW Jr, Reed SG. Adjuvants for cancer vaccines. Semin Immunol (2010) 22(3):155-61. doi:10.1016/j.smim.2010.04.007.
31. Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med (2003) 198(7):1023-34. doi:10.1084/jem.20021348.
32. Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, Jacobs JF, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res (2011) 17(17):5725-35. doi:10.1158/1078-0432.CCR-11-1261.
33. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, et al. The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments. J Cell Biol (2000) 151(3):673-84. doi:10.1083/jcb.151.3.673.
34. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med (2002) 196(12):1627-38. doi:10.1084/jem.20021598.
35. Kreutz M, Giquel B, Hu Q, Abuknesha R, Uematsu S, Akira S, et al. Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity. PLoS One (2012) 7(7):e40208. doi:10.1371/journal.pone.0040208.
36. Bouvier I, Jusforgues-Saklani H, Lim A, Lemaitre F, Lemercier B, Auriau C, et al. Immunization route dictates cross-priming efficiency and impacts the optimal timing of adjuvant delivery. Front Immunol (2011) 2:71. doi:10.3389/fimmu.2011.00071.
37. Hangalapura BN, Oosterhoff D, Gupta T, de Groot J, Wijnands PG, van Beusechem VW, et al. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Vaccine (2011) 29(12):2313-21. doi:10.1016/j.vaccine.2011.01.022.
38. Sen D, Forrest L, Kepler TB, Parker I, Cahalan MD. Selective and site-specific mobilization of dermal dendritic cells and Langerhans cells by Th1-and Th2-polarizing adjuvants. Proc Natl Acad Sci U S A (2010) 107(18):8334-9. doi:10.1073/pnas.0912817107.
39. Barrio MM, Abes R, Colombo M, Pizzurro G, Boix C, Roberti MP, et al. Human macrophages and dendritic cells can equally present MART-1 antigen to CD8(+) T cells after phagocytosis of gamma-irradiated melanoma cells. PLoS One (2012) 7(7):e40311. doi:10.1371/journal.pone.0040311.
40. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev (2012) 64(14):1547-68. doi:10.1016/j.addr.2012.04.005.
41. Suh H, Shin J, Kim YC. Microneedle patches for vaccine delivery. Clin Exp Vaccine Res (2014) 3(1):42-9. doi:10.7774/cevr.2014.3.1.42.
42. Zaric M, Lyubomska O, Touzelet O, Poux C, Al-Zahrani S, Fay F, et al. Skin dendritic cell targeting via microneedle arrays laden with antigen-encapsulated poly-D, L-lactide-co-glycolide nanoparticles induces efficient antitumor and antiviral immune responses. ACS Nano (2013) 7(3):2042-55. doi:10.1021/nn304235j.
43. Ohlfest JR, Andersen BM, Litterman AJ, Xia J, Pennell CA, Swier LE, et al. Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J Immunol (2013) 190(2):613-20. doi:10.4049/jimmunol.1201557.
44. Lindenberg JJ, Oosterhoff D, Sombroek CC, Lougheed SM, Hooijberg E, Stam AG, et al. IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation. PLoS One (2013) 8(7):e70237. doi:10.1371/journal.pone.0070237.
45. Mac Keon S, Gazzaniga S, Mallerman J, Bravo AI, Mordoh J, Wainstok R. Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue. Vaccine (2010) 28(51):8162-8. doi:10.1016/j.vaccine.2010.09.095.
46. Harris RC, Chianese-Bullock KA, Petroni GR, Schaefer JT, Brill LB II, Molhoek KR, et al. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides. J Immunother (2012) 35(1):78-88. doi:10.1097/CJI.0b013e31823731a4.
47. Liu Y, Xiao L, Joo KI, Hu B, Fang J, Wang P. In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice. Biomacromolecules (2014) 15(10):3836-45. doi:10.1021/bm501166j.
48. Purwada A, Roy K, Singh A. Engineering vaccines and niches for immune modulation. Acta Biomater (2014) 10(4):1728-40. doi:10.1016/j.actbio.2013.12.036.
49. Bobanga ID, Petrosiute A, Huang AY. Chemokines as cancer vaccine adjuvants. Vaccines (Basel) (2013) 1(4):444-62. doi:10.3390/vaccines1040444.
50. Shih NY, Yang HY, Cheng HT, Hung YM, Yao YC, Zhu YH, et al. Conditioning vaccination site with irradiated MIP-3alpha-transfected tumor cells enhances efficacy of dendritic cell-based cancer vaccine. J Immunother (2009) 32(4):363-9. doi:10.1097/CJI.0b013e31819d29d8.
51. Herrlinger U, Aulwurm S, Strik H, Weit S, Naumann U, Weller M. MIP-1alpha antagonizes the effect of a GM-CSF-enhanced subcutaneous vaccine in a mouse glioma model. J Neurooncol (2004) 66(1-2):147-54. doi:10.1023/B:NEON.0000013497.04322.fc.
52. Gnjatic S, Sawhney NB, Bhardwaj N. Toll-like receptor agonists: are they good adjuvants? Cancer J (2010) 16(4):382-91. doi:10.1097/PPO.0b013e3181eaca65.
53. Perret R, Sierro SR, Botelho NK, Corgnac S, Donda A, Romero P. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res (2013) 73(22):6597-608. doi:10.1158/0008-5472.CAN-13-0875.
54. Goldinger SM, Dummer R, Baumgaertner P, Mihic-Probst D, Schwarz K, Hammann-Haenni A, et al. Nano-particle vaccination combined with TLR-7 and-9 ligands triggers memory and effector CD8(+) T-cell responses in melanoma patients. Eur J Immunol (2012) 42(11):3049-61. doi:10.1002/eji.201142361.
55. Bright JD, Schultz HN, Byrne JA, Bright RK. Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen. Oncoimmunology (2013) 2(7):e25049. doi:10.4161/onci.25049.
56. Dang Y, Wagner WM, Gad E, Rastetter L, Berger CM, Holt GE, et al. Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin Cancer Res (2012) 18(11):3122-31. doi:10.1158/1078-0432.CCR-12-0113.
57. Fehres CM, Bruijns SC, van Beelen AJ, Kalay H, Ambrosini M, Hooijberg E, et al. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming. Eur J Immunol (2014) 44(8):2415-24. doi:10.1002/eji.201344094.
58. Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol (2011) 187(1):55-63. doi:10.4049/jimmunol.1004114.
59. Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature (2006) 440(7086):890-5. doi:10.1038/nature04651.
60. Munoz MA, Biro M, Weninger W. T cell migration in intact lymph nodes in vivo. Curr Opin Cell Biol (2014) 30C:17-24. doi:10.1016/j.ceb.2014.05.002.
61. Teijeira A, Russo E, Halin C. Taking the lymphatic route: dendritic cell migration to draining lymph nodes. Semin Immunopathol (2014) 36(2):261-74. doi:10.1007/s00281-013-0410-8.
62. Grayson MH, Ramos MS, Rohlfing MM, Kitchens R, Wang HD, Gould A, et al. Controls for lung dendritic cell maturation and migration during respiratory viral infection. J Immunol (2007) 179(3):1438-48. doi:10.4049/jimmunol.179.3.1438.
63. Miller MJ, Hejazi AS, Wei SH, Cahalan MD, Parker I. T cell repertoire scanning is promoted by dynamic dendritic cell behavior and random T cell motility in the lymph node. Proc Natl Acad Sci U S A (2004) 101(4):998-1003. doi:10.1073/pnas.0306407101.
64. Mandl JN, Liou R, Klauschen F, Vrisekoop N, Monteiro JP, Yates AJ, et al. Quantification of lymph node transit times reveals differences in antigen surveillance strategies of naive CD4+ and CD8+ T cells. Proc Natl Acad Sci U S A (2012) 109(44):18036-41. doi:10.1073/pnas.1211717109.
65. Kaiser A, Donnadieu E, Abastado JP, Trautmann A, Nardin A. CC chemokine ligand 19 secreted by mature dendritic cells increases naive T cell scanning behavior and their response to rare cognate antigen. J Immunol (2005) 175(4):2349-56. doi:10.4049/jimmunol.175.4.2349.
66. Bousso P, Robey E. Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes. Nat Immunol (2003) 4(6):579-85. doi:10.1038/ni928.
67. Hugues S, Scholer A, Boissonnas A, Nussbaum A, Combadiere C, Amigorena S, et al. Dynamic imaging of chemokine-dependent CD8+ T cell help for CD8+ T cell responses. Nat Immunol (2007) 8(9):921-30. doi:10.1038/ni1495.
68. de Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, Van Muijen GN, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res (2003) 63(1):12-7.
69. Sanchez-Sanchez N, Riol-Blanco L, Rodriguez-Fernandez JL. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J Immunol (2006) 176(9):5153-9. doi:10.4049/jimmunol.176.9.5153.
70. Chen YZ, Ruan GX, Yao XL, Li LM, Hu Y, Tabata Y, et al. Co-transfection gene delivery of dendritic cells induced effective lymph node targeting and anti-tumor vaccination. Pharm Res (2013) 30(6):1502-12. doi:10.1007/s11095-013-0985-8.
71. MartIn-Fontecha A, Sebastiani S, Hopken UE, Uguccioni M, Lipp M, Lanzavecchia A, et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med (2003) 198(4):615-21. doi:10.1084/jem.20030448.
72. Yin X, Johns SC, Kim D, Mikulski Z, Salanga CL, Handel TM, et al. Lymphatic specific disruption in the fine structure of heparan sulfate inhibits dendritic cell traffic and functional T cell responses in the lymph node. J Immunol (2014) 192(5):2133-42. doi:10.4049/jimmunol.1301286.
73. Ratzinger G, Stoitzner P, Ebner S, Lutz MB, Layton GT, Rainer C, et al. Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin. J Immunol (2002) 168(9):4361-71. doi:10.4049/jimmunol.168.9.4361.
74. Johnson LA, Jackson DG. Control of dendritic cell trafficking in lymphatics by chemokines. Angiogenesis (2014) 17(2):335-45. doi:10.1007/s10456-013-9407-0.
75. Aarntzen EH, Srinivas M, Bonetto F, Cruz LJ, Verdijk P, Schreibelt G, et al. Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. Clin Cancer Res (2013) 19(6):1525-33. doi:10.1158/1078-0432.CCR-12-1879.
76. Verdijk P, Aarntzen EH, Punt CJ, de Vries IJ, Figdor CG. Maximizing dendritic cell migration in cancer immunotherapy. Expert Opin Biol Ther (2008) 8(7):865-74. doi:10.1517/14712598.8.7.865.
77. Srinivas M, Aarntzen EH, Bulte JW, Oyen WJ, Heerschap A, de Vries IJ, et al. Imaging of cellular therapies. Adv Drug Deliv Rev (2010) 62(11):1080-93. doi:10.1016/j.addr.2010.08.009.
78. Ferguson PM, Slocombe A, Tilley RD, Hermans IF. Using magnetic resonance imaging to evaluate dendritic cell-based vaccination. PLoS One (2013) 8(5):e65318. doi:10.1371/journal.pone.0065318.
79. Munn DH, Mellor AL. The tumor-draining lymph node as an immune-privileged site. Immunol Rev (2006) 213:146-58. doi:10.1111/j.1600-065X.2006.00444.x.
80. Zheng R, Shu S. Immune response to cancer and its regulation in regional lymph nodes. J Surg Oncol (2011) 103(6):550-4. doi:10.1002/jso.21692.
81. Jeanbart L, Ballester M, de Titta A, Corthesy P, Romero P, Hubbell JA, et al. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes. Cancer Immunol Res (2014) 2(5):436-47. doi:10.1158/2326-6066.CIR-14-0019-T.
82. Boissonnas A, Scholer-Dahirel A, Simon-Blancal V, Pace L, Valet F, Kissenpfennig A, et al. Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity (2010) 32(2):266-78. doi:10.1016/j.immuni.2009.11.015.
83. Chang AY, Bhattacharya N, Mu J, Setiadi AF, Carcamo-Cavazos V, Lee GH, et al. Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients. J Transl Med (2013) 11:242. doi:10.1186/1479-5876-11-242.
84. van de Ven R, van den Hout MF, Lindenberg JJ, Sluijter BJ, van Leeuwen PA, Lougheed SM, et al. Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood (2011) 118(9):2502-10. doi:10.1182/blood-2011-03-344838.
85. St John AL, Chan CY, Staats HF, Leong KW, Abraham SN. Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. Nat Mater (2012) 11(3):250-7. doi:10.1038/nmat3222.
86. Higham EM, Wittrup KD, Chen J. Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand. J Immunol (2010) 184(7):3394-400. doi:10.4049/jimmunol.0903111.
87. Bouwer AL, Saunderson SC, Caldwell FJ, Damani TT, Pelham SJ, Dunn AC, et al. NK cells are required for dendritic cell-based immunotherapy at the time of tumor challenge. J Immunol (2014) 192(5):2514-21. doi:10.4049/jimmunol.1202797.
88. Wong JL, Muthuswamy R, Bartlett DL, Kalinski P. IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients. Oncoimmunology (2013) 2(9):e26245. doi:10.4161/onci.26245.
89. Henrickson SE, Perro M, Loughhead SM, Senman B, Stutte S, Quigley M, et al. Antigen availability determines CD8(+) T cell-dendritic cell interaction kinetics and memory fate decisions. Immunity (2013) 39(3):496-507. doi:10.1016/j.immuni.2013.08.034.
90. Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, et al. Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol (2013) 43(10):2554-65. doi:10.1002/eji.201343324.
91. Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, Keler T, et al. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Breast Cancer Res (2012) 14(2):R39. doi:10.1186/bcr3135.
92. Pizzurro GA, Madorsky Rowdo FP, Pujol-Lereis LM, Quesada-Allue LA, Copati AM, Roberti MP, et al. High lipid content of irradiated human melanoma cells does not affect cytokine-matured dendritic cell function. Cancer Immunol Immunother (2013) 62(1):3-15. doi:10.1007/s00262-012-1295-4.
93. Fox CB, Moutaftsi M, Vergara J, Desbien AL, Nana GI, Vedvick TS, et al. TLR4 ligand formulation causes distinct effects on antigen-specific cell-mediated and humoral immune responses. Vaccine (2013) 31(49):5848-55. doi:10.1016/j.vaccine.2013.09.069.
94. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Lowik MJ, Berends-van der Meer DM, Essahsah F, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A (2010) 107(26):11895-9. doi:10.1073/pnas.1006500107.
95. Valente M, Baey C, Louche P, Dutertre CA, Vimeux L, Maranon C, et al. Apoptotic cell capture by DCs induces unexpectedly robust autologous CD4+ T-cell responses. Eur J Immunol (2014) 44(8):2274-86. doi:10.1002/eji.201344191.
96. Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA. Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. Eur J Immunol (2014) 44(1):69-79. doi:10.1002/eji.201343718.
97. Schiering C, Guarnerio J, Basso V, Muzio L, Mondino A. Antigen-experienced CD4(+) T cells limit naive T-cell priming in response to therapeutic vaccination in vivo. Cancer Res (2010) 70(15):6161-70. doi:10.1158/0008-5472.CAN-09-4398.
98. Snook AE, Magee MS, Schulz S, Waldman SA. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T-or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol (2014) 44(7):1956-66. doi:10.1002/eji.201444539.
99. Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res (2013) 73(1):19-29. doi:10.1158/0008-5472.CAN-12-1127.
100. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 114(8):1537-44. doi:10.1182/blood-2008-12-195792.
101. Vasaturo A, Di Blasio S, Peeters DG, de Koning CC, de Vries JM, Figdor CG, et al. Clinical implications of co-inhibitory molecule expression in the tumor microenvironment for DC vaccination: a game of stop and go. Front Immunol (2013) 4:417. doi:10.3389/fimmu.2013.00417.
102. Idorn M, Kollgaard T, Kongsted P, Sengelov L, Thor Straten P. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother (2014) 63(11):1177-87. doi:10.1007/s00262-014-1591-2.
103. Vence L, Palucka AK, Fay JW, Ito T, Liu YJ, Banchereau J, et al. Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2007) 104(52):20884-9. doi:10.1073/pnas.0710557105.
104. Chiang CL, Kandalaft LE, Tanyi J, Hagemann AR, Motz GT, Svoronos N, et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res (2013) 19(17):4801-15. doi:10.1158/1078-0432.CCR-13-1185.
105. Takeshima T, Chamoto K, Wakita D, Ohkuri T, Togashi Y, Shirato H, et al. Local radiation therapy inhibits tumor growth through the generation of tumor-specific CTL: its potentiation by combination with Th1 cell therapy. Cancer Res (2010) 70(7):2697-706. doi:10.1158/0008-5472.CAN-09-2982.
106. Karyampudi L, Lamichhane P, Scheid AD, Kalli KR, Shreeder B, Krempski JW, et al. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody. Cancer Res (2014) 74(11):2974-85. doi:10.1158/0008-5472.CAN-13-2564.
107. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 18(8):1254-61. doi:10.1038/nm.2883.